Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Bliss

Showing results (291-300 of 378) with videos related to

Pageof 38
Sort By:
The Lancet. Oncology|November 5, 2023
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trialGalina Velikova, James P Morden, Joanne S Haviland, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 25, 2020
Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trialO Sipos, H Tovey, J Quist, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2005
Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2)S Chua, I E Smith, R P A'Hern, et al.
Breast Cancer Research : BCR|April 12, 2023
Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015)Judith M Bliss, Holly Tovey, Abigail Evans, et al.
Breast Cancer Research : BCR|January 2, 2020
Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patientsQiong Gao, Elena López-Knowles, Maggie Chon U Cheang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast CancerCharlotte Fribbens, Ben O'Leary, Lucy Kilburn, et al.
Breast Cancer Research and Treatment|November 28, 2017
Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIESM C U Cheang, J M Bliss, G Viale, et al.
Ebiomedicine|August 19, 2022
HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancerMilana A Bergamino, Elena López-Knowles, Gabriele Morani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2021
Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER<sup>+</sup>/HER2<sup>-</sup> Breast CancerMitch Dowsett, Lucy Kilburn, Mothaffar F Rimawi, et al.
JNCI Cancer Spectrum|July 31, 2019
Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor-Positive Breast CancerQiong Gao, Elena López-Knowles, Maggie Chon U Cheang, et al.
Pageof 38

Showing results (291-300 of 378) with videos related to

Sort By:
Pageof 38
The Lancet. Oncology|November 5, 2023
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trialGalina Velikova, James P Morden, Joanne S Haviland, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 25, 2020
Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trialO Sipos, H Tovey, J Quist, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2005
Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2)S Chua, I E Smith, R P A'Hern, et al.
Breast Cancer Research : BCR|April 12, 2023
Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015)Judith M Bliss, Holly Tovey, Abigail Evans, et al.
Breast Cancer Research : BCR|January 2, 2020
Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patientsQiong Gao, Elena López-Knowles, Maggie Chon U Cheang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast CancerCharlotte Fribbens, Ben O'Leary, Lucy Kilburn, et al.
Breast Cancer Research and Treatment|November 28, 2017
Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIESM C U Cheang, J M Bliss, G Viale, et al.
Ebiomedicine|August 19, 2022
HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancerMilana A Bergamino, Elena López-Knowles, Gabriele Morani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2021
Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER<sup>+</sup>/HER2<sup>-</sup> Breast CancerMitch Dowsett, Lucy Kilburn, Mothaffar F Rimawi, et al.
JNCI Cancer Spectrum|July 31, 2019
Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor-Positive Breast CancerQiong Gao, Elena López-Knowles, Maggie Chon U Cheang, et al.
Pageof 38